Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 8/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625277 | 1.00 | LMNA (0.47) | LMNABRD4DGAT2TP53MAPT | |
| SCHEMBL1624968 | 1.00 | LMNA (0.47) | LMNABRD4DGAT2TP53MAPT | |
| SCHEMBL1624332 | 0.98 | LMNA (0.46) | LMNABRD4DGAT2TP53MAPT | |
| SCHEMBL1624779 | 0.95 | LMNA (0.53) | LMNABRD4TP53MAPTHRH4 | |
| SCHEMBL1284559 | 0.93 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1284557 | 0.93 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1624583 | 0.93 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1622860 | 0.92 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL13033835 | 0.92 | BRD4 (0.49) | LMNABRD4TP53MAPTHRH4 | |
| SCHEMBL1625615 | 0.91 | LMNA (0.46) | LMNADGAT2TP53MAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | LMNA 4481/4885BRD4 458/4885DGAT2 719/4885 |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | LMNA 4481/4885BRD4 458/4885DGAT2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.